



## Clinical trial results:

### A Randomized, Double-blind, Phase 3 Study to Evaluate 6 Dose Levels of Ad26.COVS Administered As a Two-Dose Schedule in Healthy Adults

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2020-005801-14 |
| Trial protocol           | DE PL          |
| Global end of trial date | 10 July 2023   |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1               |
| This version publication date  | 07 February 2024 |
| First version publication date | 07 February 2024 |

#### Trial information

##### Trial identification

|                       |                 |
|-----------------------|-----------------|
| Sponsor protocol code | VAC31518COV3003 |
|-----------------------|-----------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT04908722 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |                                                                                              |
|------------------------------|----------------------------------------------------------------------------------------------|
| Sponsor organisation name    | Janssen Vaccines & Prevention B.V.                                                           |
| Sponsor organisation address | Archimedesweg 4-6, CN, Leiden, Netherlands, 2333                                             |
| Public contact               | Clinical Registry Group, Janssen Vaccines & Prevention B.V.,<br>ClinicalTrialsEU@its.jnj.com |
| Scientific contact           | Clinical Registry Group, Janssen Vaccines & Prevention B.V.,<br>ClinicalTrialsEU@its.jnj.com |

Notes:

#### Paediatric regulatory details

|                                                                      |    |
|----------------------------------------------------------------------|----|
| Is trial part of an agreed paediatric investigation plan (PIP)       | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

## Results analysis stage

|                                                      |                |
|------------------------------------------------------|----------------|
| Analysis stage                                       | Final          |
| Date of interim/final analysis                       | 17 August 2023 |
| Is this the analysis of the primary completion data? | No             |
| Global end of trial reached?                         | Yes            |
| Global end of trial date                             | 10 July 2023   |
| Was the trial ended prematurely?                     | No             |

Notes:

## General information about the trial

Main objective of the trial:

The main objective of this trial was to evaluate 6 dose levels of Ad26.COV2.S administered as a 2-dose schedule in healthy adults and demonstrate non-inferiority of each dose level comparing with the release titer.

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

|                                                           |              |
|-----------------------------------------------------------|--------------|
| Actual start date of recruitment                          | 18 June 2021 |
| Long term follow-up planned                               | No           |
| Independent data monitoring committee (IDMC) involvement? | Yes          |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                    |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Brazil: 811        |
| Country: Number of subjects enrolled | Germany: 368       |
| Country: Number of subjects enrolled | United States: 292 |
| Country: Number of subjects enrolled | South Africa: 122  |
| Worldwide total number of subjects   | 1593               |
| EEA total number of subjects         | 368                |

Notes:

### Subjects enrolled per age group

|                                           |      |
|-------------------------------------------|------|
| In utero                                  | 0    |
| Preterm newborn - gestational age < 37 wk | 0    |
| Newborns (0-27 days)                      | 0    |
| Infants and toddlers (28 days-23 months)  | 0    |
| Children (2-11 years)                     | 0    |
| Adolescents (12-17 years)                 | 0    |
| Adults (18-64 years)                      | 1593 |

|                     |   |
|---------------------|---|
| From 65 to 84 years | 0 |
| 85 years and over   | 0 |

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

The study involves Main study:1321 subjects were enrolled, of which 1080 completed the main study and Sub study:272 subjects were enrolled of which 231 completed the sub study. As planned, the Subject disposition, Baseline characteristics, Outcome measures data, and Adverse events data were analysed and reported combined for the Main and sub-study.

### Period 1

|                              |                                |
|------------------------------|--------------------------------|
| Period 1 title               | Overall Study (overall period) |
| Is this the baseline period? | Yes                            |
| Allocation method            | Randomised - controlled        |
| Blinding used                | Double blind                   |
| Roles blinded                | Subject, Investigator          |

### Arms

|                              |                                            |
|------------------------------|--------------------------------------------|
| Are arms mutually exclusive? | Yes                                        |
| <b>Arm title</b>             | Group 1: Ad26.COV2.S 9x10 <sup>10</sup> vp |

Arm description:

Subjects in the main study and sub study received intramuscular (IM) injection of Ad26.COV2.S 9x10<sup>10</sup> viral particles (vp) on Days 1 and 57.

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | Ad26.COV2.S            |
| Investigational medicinal product code | VAC31518               |
| Other name                             | JNJ-78436735 Ad26COVS1 |
| Pharmaceutical forms                   | Injection              |
| Routes of administration               | Intramuscular use      |

Dosage and administration details:

Subjects in the received Ad26.COV2.S 9X10<sup>10</sup> vp on Days 1 and 57.

|                  |                                            |
|------------------|--------------------------------------------|
| <b>Arm title</b> | Group 2: Ad26.COV2.S 7x10 <sup>10</sup> vp |
|------------------|--------------------------------------------|

Arm description:

Subjects in the main study received IM injection of Ad26.COV2.S 7x10<sup>10</sup> vp on Days 1 and 57.

|                                        |                        |
|----------------------------------------|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | Ad26.COV2.S            |
| Investigational medicinal product code | VAC31518               |
| Other name                             | JNJ-78436735 Ad26COVS1 |
| Pharmaceutical forms                   | Injection              |
| Routes of administration               | Intramuscular use      |

Dosage and administration details:

Subjects received Ad26.COV2.S 7x10<sup>10</sup> vp on Days 1 and 57.

|                  |                                            |
|------------------|--------------------------------------------|
| <b>Arm title</b> | Group 3: Ad26.COV2.S 5x10 <sup>10</sup> vp |
|------------------|--------------------------------------------|

Arm description:

Subjects in the main study and sub study received IM injection of Ad26.COV2.S 5x10<sup>10</sup> vp on Days 1 and 57.

|          |              |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

|                                                                                                                          |                                               |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| Investigational medicinal product name                                                                                   | Ad26.COV2.S                                   |
| Investigational medicinal product code                                                                                   | VAC31518                                      |
| Other name                                                                                                               | JNJ-78436735 Ad26COVS1                        |
| Pharmaceutical forms                                                                                                     | Injection                                     |
| Routes of administration                                                                                                 | Intramuscular use                             |
| Dosage and administration details:                                                                                       |                                               |
| Subjects received Ad26.COV2.S 5x10 <sup>10</sup> vp on Days 1 and 57.                                                    |                                               |
| <b>Arm title</b>                                                                                                         | Group 4: Ad26.COV2.S 3.5x10 <sup>10</sup> vp  |
| Arm description:                                                                                                         |                                               |
| Subjects in the main study received IM injection of Ad26.COV2.S 3.5x10 <sup>10</sup> vp on Days 1 and 57.                |                                               |
| Arm type                                                                                                                 | Experimental                                  |
| Investigational medicinal product name                                                                                   | Ad26.COV2.S                                   |
| Investigational medicinal product code                                                                                   | VAC31518                                      |
| Other name                                                                                                               | JNJ-78436735 Ad26COVS1                        |
| Pharmaceutical forms                                                                                                     | Injection                                     |
| Routes of administration                                                                                                 | Intramuscular use                             |
| Dosage and administration details:                                                                                       |                                               |
| Subjects received Ad26.COV2.S 3.5x10 <sup>10</sup> vp on Days 1 and 57.                                                  |                                               |
| <b>Arm title</b>                                                                                                         | Group 5: Ad26.COV2.S 2.5x10 <sup>10</sup> vp  |
| Arm description:                                                                                                         |                                               |
| Subjects in the main study and sub study received IM injection of Ad26.COV2.S 2.5x10 <sup>10</sup> vp on Days 1 and 57.  |                                               |
| Arm type                                                                                                                 | Experimental                                  |
| Investigational medicinal product name                                                                                   | Ad26.COV2.S                                   |
| Investigational medicinal product code                                                                                   | VAC31518                                      |
| Other name                                                                                                               | JNJ-78436735 Ad26COVS1                        |
| Pharmaceutical forms                                                                                                     | Injection                                     |
| Routes of administration                                                                                                 | Intramuscular use                             |
| Dosage and administration details:                                                                                       |                                               |
| Subjects received Ad26.COV2.S 2.5x10 <sup>10</sup> vp on Days 1 and 57.                                                  |                                               |
| <b>Arm title</b>                                                                                                         | Group 6: Ad26.COV2.S 1.25x10 <sup>10</sup> vp |
| Arm description:                                                                                                         |                                               |
| Subjects in the main study and sub study received IM injection of Ad26.COV2.S 1.25x10 <sup>10</sup> vp on Days 1 and 57. |                                               |
| Arm type                                                                                                                 | Experimental                                  |
| Investigational medicinal product name                                                                                   | Ad26.COV2.S                                   |
| Investigational medicinal product code                                                                                   | VAC31518                                      |
| Other name                                                                                                               | JNJ-78436735 Ad26COVS1                        |
| Pharmaceutical forms                                                                                                     | Injection                                     |
| Routes of administration                                                                                                 | Intramuscular use                             |
| Dosage and administration details:                                                                                       |                                               |
| Subjects received Ad26.COV2.S 1.25x10 <sup>10</sup> vp on Days 1 and 57.                                                 |                                               |

| Number of subjects in period 1        | Group 1:<br>Ad26.COV2.S | Group 2:<br>Ad26.COV2.S | Group 3:<br>Ad26.COV2.S |
|---------------------------------------|-------------------------|-------------------------|-------------------------|
| Started                               | 288                     | 221                     | 291                     |
| Main Study                            | 220 <sup>[1]</sup>      | 221                     | 222 <sup>[2]</sup>      |
| Sub Study                             | 68 <sup>[3]</sup>       | 0 <sup>[4]</sup>        | 69 <sup>[5]</sup>       |
| Per protocol immunogenicity (PPI) set | 276                     | 212                     | 282                     |
| Completed                             | 237                     | 178                     | 244                     |
| Not completed                         | 51                      | 43                      | 47                      |
| Adverse event, serious fatal          | 1                       | -                       | -                       |
| Physician decision                    | 1                       | 1                       | 1                       |
| Initiated prohibited medication       | -                       | -                       | -                       |
| Protocol deviation                    | 1                       | -                       | -                       |
| Unspecified                           | 3                       | 1                       | 3                       |
| Lost to follow-up                     | 33                      | 33                      | 36                      |
| Withdrawal by subject                 | 12                      | 8                       | 7                       |

| Number of subjects in period 1        | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |
|---------------------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|
| Started                               | 220                                                | 288                                                | 285                                                 |
| Main Study                            | 220                                                | 219 <sup>[6]</sup>                                 | 219 <sup>[7]</sup>                                  |
| Sub Study                             | 0 <sup>[8]</sup>                                   | 69 <sup>[9]</sup>                                  | 66 <sup>[10]</sup>                                  |
| Per protocol immunogenicity (PPI) set | 212                                                | 277                                                | 271                                                 |
| Completed                             | 179                                                | 240                                                | 233                                                 |
| Not completed                         | 41                                                 | 48                                                 | 52                                                  |
| Adverse event, serious fatal          | -                                                  | -                                                  | 1                                                   |
| Physician decision                    | 2                                                  | -                                                  | -                                                   |
| Initiated prohibited medication       | 1                                                  | -                                                  | 1                                                   |
| Protocol deviation                    | -                                                  | -                                                  | 1                                                   |
| Unspecified                           | 2                                                  | 4                                                  | 1                                                   |
| Lost to follow-up                     | 30                                                 | 32                                                 | 34                                                  |
| Withdrawal by subject                 | 6                                                  | 12                                                 | 14                                                  |

Notes:

[1] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in main study.

[2] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in sub study.

[3] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in sub study.

[4] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in sub study.

[5] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in main study.

[6] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in sub study.

[7] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in sub study.

[8] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in main study.

[9] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in main study.

[10] - The number of subjects at this milestone seems inconsistent with the number of subjects in the arm. It is expected that the number of subjects will be greater than, or equal to the number that completed, minus those who left.

Justification: Only reported subjects were included in main study.

## Baseline characteristics

### Reporting groups

|                                                                                                                                                                                         |                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| Reporting group title                                                                                                                                                                   | Group 1: Ad26.COV2.S 9x10 <sup>10</sup> vp    |
| Reporting group description:<br>Subjects in the main study and sub study received intramuscular (IM) injection of Ad26.COV2.S 9x10 <sup>10</sup> viral particles (vp) on Days 1 and 57. |                                               |
| Reporting group title                                                                                                                                                                   | Group 2: Ad26.COV2.S 7x10 <sup>10</sup> vp    |
| Reporting group description:<br>Subjects in the main study received IM injection of Ad26.COV2.S 7x10 <sup>10</sup> vp on Days 1 and 57.                                                 |                                               |
| Reporting group title                                                                                                                                                                   | Group 3: Ad26.COV2.S 5x10 <sup>10</sup> vp    |
| Reporting group description:<br>Subjects in the main study and sub study received IM injection of Ad26.COV2.S 5x10 <sup>10</sup> vp on Days 1 and 57.                                   |                                               |
| Reporting group title                                                                                                                                                                   | Group 4: Ad26.COV2.S 3.5x10 <sup>10</sup> vp  |
| Reporting group description:<br>Subjects in the main study received IM injection of Ad26.COV2.S 3.5x10 <sup>10</sup> vp on Days 1 and 57.                                               |                                               |
| Reporting group title                                                                                                                                                                   | Group 5: Ad26.COV2.S 2.5x10 <sup>10</sup> vp  |
| Reporting group description:<br>Subjects in the main study and sub study received IM injection of Ad26.COV2.S 2.5x10 <sup>10</sup> vp on Days 1 and 57.                                 |                                               |
| Reporting group title                                                                                                                                                                   | Group 6: Ad26.COV2.S 1.25x10 <sup>10</sup> vp |
| Reporting group description:<br>Subjects in the main study and sub study received IM injection of Ad26.COV2.S 1.25x10 <sup>10</sup> vp on Days 1 and 57.                                |                                               |

| Reporting group values                      | Group 1:<br>Ad26.COV2.S | Group 2:<br>Ad26.COV2.S | Group 3:<br>Ad26.COV2.S |
|---------------------------------------------|-------------------------|-------------------------|-------------------------|
| Number of subjects                          | 288                     | 221                     | 291                     |
| Title for AgeCategorical<br>Units: subjects |                         |                         |                         |
| Children (2-11 years)                       | 0                       | 0                       | 0                       |
| Adolescents (12-17 years)                   | 0                       | 0                       | 0                       |
| Adults (18-64 years)                        | 288                     | 221                     | 291                     |
| From 65 to 84 years                         | 0                       | 0                       | 0                       |
| 85 years and over                           | 0                       | 0                       | 0                       |
| Title for AgeContinuous<br>Units: years     |                         |                         |                         |
| arithmetic mean                             | 35.6                    | 35.2                    | 34.8                    |
| standard deviation                          | ± 10.21                 | ± 9.87                  | ± 9.82                  |
| Title for Gender<br>Units: subjects         |                         |                         |                         |
| Female                                      | 117                     | 73                      | 119                     |
| Male                                        | 170                     | 148                     | 172                     |
| Undifferentiated                            | 1                       | 0                       | 0                       |

| Reporting group values | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |
|------------------------|----------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|
| Number of subjects     | 220                                                | 288                                                | 285                                                 |

|                                             |        |        |        |
|---------------------------------------------|--------|--------|--------|
| Title for AgeCategorical<br>Units: subjects |        |        |        |
| Children (2-11 years)                       | 0      | 0      | 0      |
| Adolescents (12-17 years)                   | 0      | 0      | 0      |
| Adults (18-64 years)                        | 220    | 288    | 285    |
| From 65 to 84 years                         | 0      | 0      | 0      |
| 85 years and over                           | 0      | 0      | 0      |
| Title for AgeContinuous<br>Units: years     |        |        |        |
| arithmetic mean                             | 34.7   | 34.5   | 33.4   |
| standard deviation                          | ± 9.36 | ± 9.81 | ± 9.63 |
| Title for Gender<br>Units: subjects         |        |        |        |
| Female                                      | 72     | 106    | 103    |
| Male                                        | 148    | 182    | 182    |
| Undifferentiated                            | 0      | 0      | 0      |

|                                             |       |  |  |
|---------------------------------------------|-------|--|--|
| <b>Reporting group values</b>               | Total |  |  |
| Number of subjects                          | 1593  |  |  |
| Title for AgeCategorical<br>Units: subjects |       |  |  |
| Children (2-11 years)                       | 0     |  |  |
| Adolescents (12-17 years)                   | 0     |  |  |
| Adults (18-64 years)                        | 1593  |  |  |
| From 65 to 84 years                         | 0     |  |  |
| 85 years and over                           | 0     |  |  |
| Title for AgeContinuous<br>Units: years     |       |  |  |
| arithmetic mean                             |       |  |  |
| standard deviation                          | -     |  |  |
| Title for Gender<br>Units: subjects         |       |  |  |
| Female                                      | 590   |  |  |
| Male                                        | 1002  |  |  |
| Undifferentiated                            | 1     |  |  |

## End points

### End points reporting groups

|                                                                                                                                                                                         |                                               |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| Reporting group title                                                                                                                                                                   | Group 1: Ad26.COVS.S 9x10 <sup>10</sup> vp    |
| Reporting group description:<br>Subjects in the main study and sub study received intramuscular (IM) injection of Ad26.COVS.S 9x10 <sup>10</sup> viral particles (vp) on Days 1 and 57. |                                               |
| Reporting group title                                                                                                                                                                   | Group 2: Ad26.COVS.S 7x10 <sup>10</sup> vp    |
| Reporting group description:<br>Subjects in the main study received IM injection of Ad26.COVS.S 7x10 <sup>10</sup> vp on Days 1 and 57.                                                 |                                               |
| Reporting group title                                                                                                                                                                   | Group 3: Ad26.COVS.S 5x10 <sup>10</sup> vp    |
| Reporting group description:<br>Subjects in the main study and sub study received IM injection of Ad26.COVS.S 5x10 <sup>10</sup> vp on Days 1 and 57.                                   |                                               |
| Reporting group title                                                                                                                                                                   | Group 4: Ad26.COVS.S 3.5x10 <sup>10</sup> vp  |
| Reporting group description:<br>Subjects in the main study received IM injection of Ad26.COVS.S 3.5x10 <sup>10</sup> vp on Days 1 and 57.                                               |                                               |
| Reporting group title                                                                                                                                                                   | Group 5: Ad26.COVS.S 2.5x10 <sup>10</sup> vp  |
| Reporting group description:<br>Subjects in the main study and sub study received IM injection of Ad26.COVS.S 2.5x10 <sup>10</sup> vp on Days 1 and 57.                                 |                                               |
| Reporting group title                                                                                                                                                                   | Group 6: Ad26.COVS.S 1.25x10 <sup>10</sup> vp |
| Reporting group description:<br>Subjects in the main study and sub study received IM injection of Ad26.COVS.S 1.25x10 <sup>10</sup> vp on Days 1 and 57.                                |                                               |

### Primary: Geometric Mean Concentration of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Geometric Mean Concentration of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 28 Days After First Vaccination <sup>[1]</sup> |
| End point description:<br>Geometric mean concentration of SARS-CoV-2 S protein binding antibodies measured by ELISA were reported. As per planned analysis, the data were analysed and reported combined for the main study and sub-study. The per protocol immunogenicity set included all randomised and vaccinated subjects for whom immunogenicity data were available excluding subjects with major protocol deviations expected to impact the immunogenicity outcomes. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint. |                                                                                                                                                                                                                                |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary                                                                                                                                                                                                                        |
| End point timeframe:<br>28 days after first vaccination (at Day 29)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                |
| Notes:<br>[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.<br>Justification: Descriptive statistics was done, no inferential statistical analysis was performed.                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                |

| End point values                          | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
|-------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Subject group type                        | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed               | 249                                              | 191                                              | 250                                              | 189                                                |
| Units: ELISA Units per millilitre (EU/mL) |                                                  |                                                  |                                                  |                                                    |
| geometric mean (confidence interval 95%)  | 2351 (1849 to 2989)                              | 1714 (1305 to 2250)                              | 2189 (1726 to 2775)                              | 1377 (1062 to 1786)                                |

| End point values                          | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
|-------------------------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type                        | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed               | 243                                                | 251                                                 |  |  |
| Units: ELISA Units per millilitre (EU/mL) |                                                    |                                                     |  |  |
| geometric mean (confidence interval 95%)  | 1626 (1255 to 2106)                                | 1976 (1521 to 2566)                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Geometric Mean Ratio of Antibodies Measured by S-ELISA at 28 Days After First Vaccination

|                 |                                                                                                                         |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|
| End point title | Geometric Mean Ratio of Antibodies Measured by S-ELISA at 28 Days After First Vaccination <sup>[2]</sup> <sup>[3]</sup> |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|

End point description:

Geometric mean ratio of antibodies measured by S-ELISA were reported. Geometric mean ratio was calculated as ratio of 1 dose of Ad26.COV2.S 9x10<sup>10</sup> vp, Ad26.COV2.S 7x10<sup>10</sup> vp, Ad26.COV2.S 3.5x10<sup>10</sup>, Ad26.COV2.S 2.5x10<sup>10</sup>, and Ad26.COV2.S 1.25x10<sup>10</sup> vp divided by 1 dose of Ad26.COV2.S 5x10<sup>10</sup> vp at Day 29. As per planned analysis, the data were analysed and reported combined for the main study and sub-study. The per protocol immunogenicity set included all randomized and vaccinated subjects for whom immunogenicity data were available excluding subjects with major protocol deviations expected to impact the immunogenicity outcomes. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this end point.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Day 29 (28 days post dose 1)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical Analysis was not planned for all the arms of Baseline period.

| End point values                           | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp |
|--------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Subject group type                         | Reporting group                                  | Reporting group                                  | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed                | 249                                              | 191                                              | 189                                                | 243                                                |
| Units: Ratio                               |                                                  |                                                  |                                                    |                                                    |
| geometric mean (confidence interval 97.5%) | 1.15 (0.926 to 1.440)                            | 1.07 (0.844 to 1.356)                            | 0.94 (0.742 to 1.193)                              | 0.80 (0.641 to 1.00)                               |

| End point values                           | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |  |
|--------------------------------------------|-----------------------------------------------------|--|--|--|
| Subject group type                         | Reporting group                                     |  |  |  |
| Number of subjects analysed                | 251                                                 |  |  |  |
| Units: Ratio                               |                                                     |  |  |  |
| geometric mean (confidence interval 97.5%) | 0.81 (0.648 to 1.007)                               |  |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Geometric Mean Concentration of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 14 Days After Second Vaccination

|                 |                                                                                                                                                                                                                                 |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| End point title | Geometric Mean Concentration of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) S Protein Binding Antibodies Measured by Enzyme-Linked Immunosorbent Assay (ELISA) 14 Days After Second Vaccination <sup>[4]</sup> |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

End point description:

Geometric mean concentration of SARS-CoV-2 S protein binding antibodies measured by ELISA were reported. As per planned analysis, the data were analysed and reported combined for the main study and sub-study. The per protocol immunogenicity set included all randomised and vaccinated subjects for whom immunogenicity data were available excluding subjects with major protocol deviations expected to impact the immunogenicity outcomes. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this endpoint.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

14 days after second vaccination (at Day 71)

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

| End point values                          | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
|-------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Subject group type                        | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed               | 171                                              | 130                                              | 180                                              | 134                                                |
| Units: ELISA Units per millilitre (EU/mL) |                                                  |                                                  |                                                  |                                                    |
| geometric mean (confidence interval 95%)  | 4997 (4145 to 6023)                              | 3757 (3030 to 4659)                              | 3855 (3185 to 4666)                              | 3460 (2781 to 4304)                                |

| End point values                          | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
|-------------------------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type                        | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed               | 172                                                | 184                                                 |  |  |
| Units: ELISA Units per millilitre (EU/mL) |                                                    |                                                     |  |  |
| geometric mean (confidence interval 95%)  | 3641 (2969 to 4465)                                | 3905 (3113 to 4897)                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Primary: Geometric Mean Ratio of Antibodies Measured by S-ELISA 14 Days After Second Vaccination

|                 |                                                                                                           |
|-----------------|-----------------------------------------------------------------------------------------------------------|
| End point title | Geometric Mean Ratio of Antibodies Measured by S-ELISA 14 Days After Second Vaccination <sup>[5][6]</sup> |
|-----------------|-----------------------------------------------------------------------------------------------------------|

End point description:

Geometric mean ratio of antibodies measured by S-ELISA were reported. Geometric mean ratio was calculated as ratio of 2 doses on Day 71 dose of Ad26.COV2.S 9x10<sup>10</sup> vp, Ad26.COV2.S 7x10<sup>10</sup> vp, Ad26.COV2.S 3.5x10<sup>10</sup>, Ad26.COV2.S 2.5x10<sup>10</sup>, and Ad26.COV2.S 1.25x10<sup>10</sup> vp divided by 1 dose of Ad26.COV2.S 5x10<sup>10</sup> vp at Day 29 and values observed at post-vaccination on Day 71 of 2 doses of Ad26.COV2.S 9x10<sup>10</sup> vp, Ad26.COV2.S 7x10<sup>10</sup> vp, Ad26.COV2.S 3.5x10<sup>10</sup>, Ad26.COV2.S 2.5x10<sup>10</sup>, and Ad26.COV2.S 1.25x10<sup>10</sup> vp divided by 2 doses for Ad26.COV2.S 5x10<sup>10</sup> vp at Day 71. As per planned analysis, the data were analysed and reported combined for the main study and sub-study. The per protocol immunogenicity set included all randomised and vaccinated subjects for whom immunogenicity data were available excluding subjects with major protocol deviations expected to impact the immunogenicity outcomes. N (number of subjects analysed): subjects who were evaluable for this outcome measure.

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Group 3: 28 days after first vaccination (Day 29), 14 days after second vaccination (Day 71); Groups 1, 2, 4, 5, and 6: 14 days after second vaccination (Day 71)

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed.

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical Analysis was not planned for all the arms of Baseline period.

| End point values                           | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp |
|--------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Subject group type                         | Reporting group                                  | Reporting group                                  | Reporting group                                    | Reporting group                                    |
| Number of subjects analysed                | 171                                              | 130                                              | 134                                                | 172                                                |
| Units: Ratio                               |                                                  |                                                  |                                                    |                                                    |
| geometric mean (confidence interval 97.5%) |                                                  |                                                  |                                                    |                                                    |
| 2 doses at Day 71/1 dose at Day 29         | 2.53 (1.992 to 3.207)                            | 2.37 (1.829 to 3.077)                            | 2.20 (1.697 to 2.841)                              | 1.79 (1.408 to 2.265)                              |

|                                      |                       |                       |                       |                       |
|--------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| 2 doses at Day 71/ 2 doses at Day 71 | 1.41 (1.088 to 1.815) | 1.32 (1.000 to 1.739) | 1.22 (0.928 to 1.606) | 0.99 (0.769 to 1.282) |
|--------------------------------------|-----------------------|-----------------------|-----------------------|-----------------------|

|                                            |                                                     |  |  |  |
|--------------------------------------------|-----------------------------------------------------|--|--|--|
| <b>End point values</b>                    | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |  |
| Subject group type                         | Reporting group                                     |  |  |  |
| Number of subjects analysed                | 184                                                 |  |  |  |
| Units: Ratio                               |                                                     |  |  |  |
| geometric mean (confidence interval 97.5%) |                                                     |  |  |  |
| 2 doses at Day 71/1 dose at Day 29         | 1.70 (1.348 to 2.148)                               |  |  |  |
| 2 doses at Day 71/ 2 doses at Day 71       | 0.95 (0.736 to 1.217)                               |  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percentage of Subjects with Serological Response to Vaccination to SARS-COV-2 S Protein as Measured by ELISA

|                 |                                                                                                              |
|-----------------|--------------------------------------------------------------------------------------------------------------|
| End point title | Percentage of Subjects with Serological Response to Vaccination to SARS-COV-2 S Protein as Measured by ELISA |
|-----------------|--------------------------------------------------------------------------------------------------------------|

End point description:

Percentage of subjects with serological response to vaccination to SARS-COV-2 S Protein as Measured by ELISA were reported. A subject was considered a responder if one or both of the following conditions were satisfied: (1) the baseline (pre-dose 1) sample value was less than or equal to ( $\leq$ ) lower limit of quantification (LLOQ) and the post-baseline sample was greater than ( $>$ ) LLOQ; (2) the baseline sample (pre-dose 1) value was  $>$ LLOQ and the post-baseline sample value represented an at least 4-fold ( $\geq 4$ -fold) increase from the baseline sample value. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. The per protocol immunogenicity set included all randomised and vaccinated subjects for whom immunogenicity data were available excluding subjects with major protocol deviations expected to impact the immunogenicity outcomes.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 60

|                                    |                                                  |                                                  |                                                  |                                                    |
|------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| <b>End point values</b>            | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
| Subject group type                 | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed        | 249                                              | 191                                              | 250                                              | 189                                                |
| Units: Percentage of subjects      |                                                  |                                                  |                                                  |                                                    |
| number (not applicable)            |                                                  |                                                  |                                                  |                                                    |
| Day 29 (n=249,191,250,189,243,251) | 82.7                                             | 90.1                                             | 78.8                                             | 87.8                                               |
| Day 57 (n=216,167,217,162,219,220) | 81.9                                             | 88.6                                             | 80.2                                             | 92.0                                               |
| Day 71 (n=171,130,180,134,172,184) | 81.9                                             | 92.3                                             | 79.4                                             | 91.8                                               |
| Week 32 (n=112,86,128,90,121,136)  | 72.3                                             | 83.7                                             | 68.0                                             | 86.7                                               |

|                               |      |      |      |      |
|-------------------------------|------|------|------|------|
| Week 60 (n=45,33,42,37,45,52) | 68.9 | 81.8 | 61.9 | 83.8 |
|-------------------------------|------|------|------|------|

| End point values                   | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
|------------------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type                 | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed        | 243                                                | 251                                                 |  |  |
| Units: Percentage of subjects      |                                                    |                                                     |  |  |
| number (not applicable)            |                                                    |                                                     |  |  |
| Day 29 (n=249,191,250,189,243,251) | 80.2                                               | 76.1                                                |  |  |
| Day 57 (n=216,167,217,162,219,220) | 81.3                                               | 77.7                                                |  |  |
| Day 71 (n=171,130,180,134,172,184) | 80.8                                               | 76.1                                                |  |  |
| Week 32 (n=112,86,128,90,121,136)  | 68.6                                               | 63.2                                                |  |  |
| Week 60 (n=45,33,42,37,45,52)      | 60.0                                               | 53.8                                                |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Geometric Mean Concentration of SARS-CoV-2 S Protein Binding Antibody Measured by ELISA

|                 |                                                                                         |
|-----------------|-----------------------------------------------------------------------------------------|
| End point title | Geometric Mean Concentration of SARS-CoV-2 S Protein Binding Antibody Measured by ELISA |
|-----------------|-----------------------------------------------------------------------------------------|

End point description:

Geometric mean concentration of SARS-CoV-2 S protein binding antibody measured by ELISA were reported. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. The per protocol immunogenicity set included all randomised and vaccinated subjects for whom immunogenicity data were available excluding subjects with major protocol deviations expected to impact the immunogenicity outcomes. Here, 'N' (number of subjects analysed) signifies subjects who were evaluable for this end point.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to Week 60

| End point values                         | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
|------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Subject group type                       | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed              | 249                                              | 191                                              | 250                                              | 189                                                |
| Units: ELISA Unit (EU)/mL                |                                                  |                                                  |                                                  |                                                    |
| geometric mean (confidence interval 95%) |                                                  |                                                  |                                                  |                                                    |
| Day 29 (n=249,191,250,189,243,251)       | 2351 (1849 to 2989)                              | 1714 (1305 to 2250)                              | 2189 (1726 to 2775)                              | 1377 (1062 to 1786)                                |
| Day 57 (n=216,167,217,162,219,220)       | 2722 (2156 to 3438)                              | 1842 (1404 to 2417)                              | 2089 (1651 to 2643)                              | 1622 (1233 to 2134)                                |
| Day 71 (n=171,130,180,134,172,184)       | 4997 (4145 to 6023)                              | 3757 (3030 to 4659)                              | 3855 (3185 to 4666)                              | 3460 (2781 to 4304)                                |

|                                   |                     |                     |                     |                     |
|-----------------------------------|---------------------|---------------------|---------------------|---------------------|
| Week 32 (n=112,86,128,90,121,136) | 3331 (2499 to 4438) | 2903 (2706 to 4058) | 2616 (2001 to 3420) | 2059 (1470 to 2885) |
| Week 60 (n=45,33,42,37,45,52)     | 4968 (3119 to 7915) | 5010 (3146 to 7981) | 2363 (1448 to 3857) | 2191 (1224 to 3921) |

| End point values                         | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
|------------------------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type                       | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed              | 243                                                | 251                                                 |  |  |
| Units: ELISA Unit (EU)/mL                |                                                    |                                                     |  |  |
| geometric mean (confidence interval 95%) |                                                    |                                                     |  |  |
| Day 29 (n=249,191,250,189,243,251)       | 1626 (1255 to 2106)                                | 1976 (1521 to 2566)                                 |  |  |
| Day 57 (n=216,167,217,162,219,220)       | 1919 (1481 to 2486)                                | 2293 (1766 to 2978)                                 |  |  |
| Day 71 (n=171,130,180,134,172,184)       | 3641 (2969 to 4465)                                | 3905 (3113 to 4897)                                 |  |  |
| Week 32 (n=112,86,128,90,121,136)        | 3067 (2268 to 4148)                                | 2707 (2000 to 3662)                                 |  |  |
| Week 60 (n=45,33,42,37,45,52)            | 2769 (1776 to 4317)                                | 3664 (2169 to 6190)                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination

|                 |                                                                                                |
|-----------------|------------------------------------------------------------------------------------------------|
| End point title | Number of Subjects with Solicited Local Adverse Events (AEs) for 7 Days After Each Vaccination |
|-----------------|------------------------------------------------------------------------------------------------|

End point description:

An AE was any untoward medical occurrence in a subject participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited local AEs were pre-defined local (at the injection site) AEs for which subjects were specifically questioned and which were noted by subject in their e-diary for 7 days after each vaccination. Solicited local AEs included injection site pain/tenderness, erythema and swelling at the study vaccine injection site. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. Full analysis set included all subjects with at least one vaccine administration documented. Here, 'n' (number of subjects analysed) signifies number of subjects evaluable for this timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

7 days after each vaccination (first [1st] vaccination [at Day 8], second [2nd] vaccination [at Day 64])

| End point values                                     | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
|------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Subject group type                                   | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed                          | 288                                              | 221                                              | 291                                              | 220                                                |
| Units: Subjects                                      |                                                  |                                                  |                                                  |                                                    |
| After 1st vaccination<br>(n=288,221,291,220,288,285) | 179                                              | 143                                              | 162                                              | 137                                                |
| After 2nd vaccination<br>(n=264,200,269,199,270,258) | 130                                              | 100                                              | 124                                              | 95                                                 |

| End point values                                     | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
|------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type                                   | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed                          | 288                                                | 285                                                 |  |  |
| Units: Subjects                                      |                                                    |                                                     |  |  |
| After 1st vaccination<br>(n=288,221,291,220,288,285) | 155                                                | 133                                                 |  |  |
| After 2nd vaccination<br>(n=264,200,269,199,270,258) | 111                                                | 104                                                 |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Solicited Systemic AEs for 7 Days After Each Vaccination

|                 |                                                                                  |
|-----------------|----------------------------------------------------------------------------------|
| End point title | Number of Subjects with Solicited Systemic AEs for 7 Days After Each Vaccination |
|-----------------|----------------------------------------------------------------------------------|

End point description:

An AE was any untoward medical occurrence in a subject participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Solicited systemic AEs (include body temperature, fatigue, headache, nausea, myalgia) were noted in the subject diary after 7 days of each vaccination. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. Full analysis set included all subjects with at least one vaccine administration documented. Here, 'n' (number of subjects analysed) signifies number of subjects evaluable for this timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

7 days after each vaccination (1st vaccination [at Day 8], 2nd vaccination [at Day 64])

| End point values            | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
|-----------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Subject group type          | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed | 288                                              | 221                                              | 291                                              | 220                                                |
| Units: Subjects             |                                                  |                                                  |                                                  |                                                    |

|                                                      |     |     |     |     |
|------------------------------------------------------|-----|-----|-----|-----|
| After 1st vaccination<br>(n=288,221,291,220,288,285) | 204 | 156 | 173 | 135 |
| After 2nd vaccination<br>(n=264,200,269,199,270,258) | 144 | 98  | 111 | 91  |

| End point values                                     | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
|------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type                                   | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed                          | 288                                                | 285                                                 |  |  |
| Units: Subjects                                      |                                                    |                                                     |  |  |
| After 1st vaccination<br>(n=288,221,291,220,288,285) | 156                                                | 152                                                 |  |  |
| After 2nd vaccination<br>(n=264,200,269,199,270,258) | 105                                                | 109                                                 |  |  |

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects with Unsolicited AEs for 28 Days After Each Vaccination

|                 |                                                                            |
|-----------------|----------------------------------------------------------------------------|
| End point title | Number of Subjects with Unsolicited AEs for 28 Days After Each Vaccination |
|-----------------|----------------------------------------------------------------------------|

End point description:

Unsolicited AEs were all AEs for which the subject was not specifically questioned in the subject diary. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. Full analysis set included all subjects with at least one vaccine administration documented. Here, 'n' (number of subjects analysed) signifies number of subjects evaluable for this timepoint.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

28 days after each vaccination (1st vaccination [at Day 29], 2nd vaccination [at Day 85])

| End point values                                     | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
|------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Subject group type                                   | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed                          | 288                                              | 221                                              | 291                                              | 220                                                |
| Units: Subjects                                      |                                                  |                                                  |                                                  |                                                    |
| After 1st vaccination<br>(n=288,221,291,220,288,285) | 78                                               | 60                                               | 55                                               | 58                                                 |
| After 2nd vaccination<br>(n=264,200,269,199,270,258) | 55                                               | 28                                               | 49                                               | 39                                                 |

| End point values | Group 5:<br>Ad26.COV2.S | Group 6:<br>Ad26.COV2.S |  |  |
|------------------|-------------------------|-------------------------|--|--|
|------------------|-------------------------|-------------------------|--|--|

|                                                      | x10 <sup>10</sup> vp | x10 <sup>10</sup> vp |  |  |
|------------------------------------------------------|----------------------|----------------------|--|--|
| Subject group type                                   | Reporting group      | Reporting group      |  |  |
| Number of subjects analysed                          | 288                  | 285                  |  |  |
| Units: Subjects                                      |                      |                      |  |  |
| After 1st vaccination<br>(n=288,221,291,220,288,285) | 69                   | 59                   |  |  |
| After 2nd vaccination<br>(n=264,200,269,199,270,258) | 53                   | 50                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Serious Adverse Events (SAEs)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                       |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|
| End point title                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Number of Subjects with Serious Adverse Events (SAEs) |
| End point description:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                       |
| SAE was any untoward medical occurrence that at any dose may resulted in death, was life-threatening, required inpatient hospitalisation or prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via a medicinal product. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. Full analysis set included all subjects with at least one vaccine administration documented. |                                                       |
| End point type                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Secondary                                             |
| End point timeframe:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                       |
| From Day 1 (post-vaccination) up to end of the study (up to 60 weeks)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                       |

| End point values            | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
|-----------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| Subject group type          | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed | 288                                              | 221                                              | 291                                              | 220                                                |
| Units: Subjects             | 13                                               | 3                                                | 4                                                | 4                                                  |

| End point values            | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
|-----------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| Subject group type          | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed | 288                                                | 285                                                 |  |  |
| Units: Subjects             | 3                                                  | 5                                                   |  |  |

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Number of Subjects with Adverse Events of Special Interest (AESIs)**

---

|                 |                                                                    |
|-----------------|--------------------------------------------------------------------|
| End point title | Number of Subjects with Adverse Events of Special Interest (AESIs) |
|-----------------|--------------------------------------------------------------------|

End point description:

AESIs were significant AEs that were judged to be of special interest because of clinical importance, known or suspected class effects, or based on nonclinical signals. Thrombosis with thrombocytopenia syndrome were considered to be an AESI. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. Full analysis set included all subjects with at least one vaccine administration documented.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

From Day 1 (post-vaccination) up to end of the study (up to 60 weeks)

---

|                             |                                                  |                                                  |                                                  |                                                    |
|-----------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| <b>End point values</b>     | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
| Subject group type          | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed | 288                                              | 221                                              | 291                                              | 220                                                |
| Units: Subjects             | 0                                                | 0                                                | 0                                                | 0                                                  |

|                             |                                                    |                                                     |  |  |
|-----------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| <b>End point values</b>     | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
| Subject group type          | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed | 288                                                | 285                                                 |  |  |
| Units: Subjects             | 0                                                  | 0                                                   |  |  |

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Secondary: Number of Subjects with AEs Leading to Study Discontinuation**

---

|                 |                                                              |
|-----------------|--------------------------------------------------------------|
| End point title | Number of Subjects with AEs Leading to Study Discontinuation |
|-----------------|--------------------------------------------------------------|

End point description:

Number of subjects with AEs leading to study discontinuation were reported. Full analysis set included all subjects with at least one vaccine administration documented.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Up to 60 weeks

---

|                             |                                                  |                                                  |                                                  |                                                    |
|-----------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| <b>End point values</b>     | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
| Subject group type          | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed | 288                                              | 221                                              | 291                                              | 220                                                |
| Units: Subjects             | 0                                                | 0                                                | 0                                                | 0                                                  |

|                             |                                                    |                                                     |  |  |
|-----------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| <b>End point values</b>     | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
| Subject group type          | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed | 288                                                | 285                                                 |  |  |
| Units: Subjects             | 0                                                  | 0                                                   |  |  |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects with Medically-Attended Adverse Events (MAAEs)

|                 |                                                                   |
|-----------------|-------------------------------------------------------------------|
| End point title | Number of Subjects with Medically-Attended Adverse Events (MAAEs) |
|-----------------|-------------------------------------------------------------------|

End point description:

MAAEs were defined as AEs with medically-attended visits including hospital, emergency room, urgent care clinic, or other visits to or from medical personnel for any reason. Routine study visits were not considered medically-attended visits. New onset of chronic diseases were collected as part of the MAAEs. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study. Full analysis set included all subjects with at least one vaccine administration documented.

|                |           |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

6 months after second vaccination (up to 32 weeks)

|                             |                                                  |                                                  |                                                  |                                                    |
|-----------------------------|--------------------------------------------------|--------------------------------------------------|--------------------------------------------------|----------------------------------------------------|
| <b>End point values</b>     | Group 1:<br>Ad26.COV2.S<br>9x10 <sup>10</sup> vp | Group 2:<br>Ad26.COV2.S<br>7x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S<br>5x10 <sup>10</sup> vp | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp |
| Subject group type          | Reporting group                                  | Reporting group                                  | Reporting group                                  | Reporting group                                    |
| Number of subjects analysed | 288                                              | 221                                              | 281                                              | 220                                                |
| Units: Subjects             | 54                                               | 34                                               | 50                                               | 35                                                 |

|                             |                                                    |                                                     |  |  |
|-----------------------------|----------------------------------------------------|-----------------------------------------------------|--|--|
| <b>End point values</b>     | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |  |  |
| Subject group type          | Reporting group                                    | Reporting group                                     |  |  |
| Number of subjects analysed | 288                                                | 285                                                 |  |  |
| Units: Subjects             | 48                                                 | 35                                                  |  |  |

## **Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Day 1 (post-vaccination) up to end of the study (i.e. up to 60 weeks)

Adverse event reporting additional description:

Full analysis set included all subjects with at least one vaccine administration documented. As per planned analysis, the data were analyzed and reported combined for the main study and sub-study.

|                 |                |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 26.0 |
|--------------------|------|

### Reporting groups

|                       |                                            |
|-----------------------|--------------------------------------------|
| Reporting group title | Group 1: Ad26.COV2.S 9x10 <sup>10</sup> vp |
|-----------------------|--------------------------------------------|

Reporting group description:

Subjects in the main and sub study received a single dose of IM injection of Ad26.COV2.S 9x10<sup>10</sup> vp on Days 1 and 57.

|                       |                                            |
|-----------------------|--------------------------------------------|
| Reporting group title | Group 2: Ad26.COV2.S 7x10 <sup>10</sup> vp |
|-----------------------|--------------------------------------------|

Reporting group description:

Subjects in the main study received a single dose of IM injection of Ad26.COV2.S 7x10<sup>10</sup> vp on Days 1 and 57.

|                       |                                               |
|-----------------------|-----------------------------------------------|
| Reporting group title | Group 6: Ad26.COV2.S 1.25x10 <sup>10</sup> vp |
|-----------------------|-----------------------------------------------|

Reporting group description:

Subjects in the main and sub study received a single dose of IM injection of Ad26.COV2.S 1.25x10<sup>10</sup> vp on Days 1 and 57.

|                       |                                              |
|-----------------------|----------------------------------------------|
| Reporting group title | Group 4: Ad26.COV2.S 3.5x10 <sup>10</sup> vp |
|-----------------------|----------------------------------------------|

Reporting group description:

Subjects in the main received a single dose of IM injection of Ad26.COV2.S 3.5x10<sup>10</sup> vp on Days 1 and 57.

|                       |                                              |
|-----------------------|----------------------------------------------|
| Reporting group title | Group 5: Ad26.COV2.S 2.5x10 <sup>10</sup> vp |
|-----------------------|----------------------------------------------|

Reporting group description:

Subjects in the main and sub study received a single dose of IM injection of Ad26.COV2.S 2.5x10<sup>10</sup> vp on Days 1 and 57.

|                       |                                            |
|-----------------------|--------------------------------------------|
| Reporting group title | Group 3: Ad26.COV2.S 5x10 <sup>10</sup> vp |
|-----------------------|--------------------------------------------|

Reporting group description:

Subjects in the main and sub study received a single dose of IM injection of Ad26.COV2.S 5x10<sup>10</sup> vp on Days 1 and 57.

| Serious adverse events                                              | Group 1:<br>Ad26.COV2.S | Group 2:<br>Ad26.COV2.S | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |
|---------------------------------------------------------------------|-------------------------|-------------------------|-----------------------------------------------------|
| Total subjects affected by serious adverse events                   |                         |                         |                                                     |
| subjects affected / exposed                                         | 13 / 288 (4.51%)        | 3 / 221 (1.36%)         | 5 / 285 (1.75%)                                     |
| number of deaths (all causes)                                       | 1                       | 0                       | 1                                                   |
| number of deaths resulting from adverse events                      |                         |                         |                                                     |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) |                         |                         |                                                     |
| Tongue Neoplasm Malignant Stage Unspecified                         |                         |                         |                                                     |

|                                                      |                 |                 |                 |
|------------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                          | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Pregnancy, puerperium and perinatal conditions       |                 |                 |                 |
| Abortion Spontaneous                                 |                 |                 |                 |
| subjects affected / exposed                          | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Gestational Diabetes                                 |                 |                 |                 |
| subjects affected / exposed                          | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 1 / 285 (0.35%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| General disorders and administration site conditions |                 |                 |                 |
| Drowning                                             |                 |                 |                 |
| subjects affected / exposed                          | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 1           | 0 / 0           | 0 / 0           |
| Death                                                |                 |                 |                 |
| subjects affected / exposed                          | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 1 / 285 (0.35%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 1           |
| Reproductive system and breast disorders             |                 |                 |                 |
| Hydrosalpinx                                         |                 |                 |                 |
| subjects affected / exposed                          | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Cyst Torsion                                 |                 |                 |                 |
| subjects affected / exposed                          | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 1 / 285 (0.35%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Disorder                                     |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 1 / 285 (0.35%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Vaginal Haemorrhage                             |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 1 / 221 (0.45%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Respiratory, thoracic and mediastinal disorders |                 |                 |                 |
| Pleural Effusion                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Anxiety Disorder                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 1 / 285 (0.35%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Anxiety                                         |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Depression                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 1 / 221 (0.45%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychotic Disorder                              |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Suicide Attempt                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Injury, poisoning and procedural complications  |                 |                 |                 |
| Ankle Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 1 / 221 (0.45%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gun Shot Wound                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Stab Wound                                      |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |
| Myopericarditis                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Carotid Artery Dissection                       |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Paraesthesia                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Myasthenia Gravis                               |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Syncope                                         |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood and lymphatic system disorders            |                 |                 |                 |
| Anaemia                                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gastrointestinal disorders                      |                 |                 |                 |
| Abdominal Pain                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Anal Fistula                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 1 / 285 (0.35%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| Cholelithiasis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Nephrolithiasis                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Intervertebral Disc Protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| Appendicitis                                    |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Cellulitis</b>                               |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Pelvic Abscess</b>                           |                 |                 |                 |
| subjects affected / exposed                     | 1 / 288 (0.35%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Pyelonephritis</b>                           |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| <b>Pyelonephritis Acute</b>                     |                 |                 |                 |
| subjects affected / exposed                     | 0 / 288 (0.00%) | 0 / 221 (0.00%) | 0 / 285 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

| <b>Serious adverse events</b>                                              | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S |
|----------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------|
| <b>Total subjects affected by serious adverse events</b>                   |                                                    |                                                    |                         |
| subjects affected / exposed                                                | 4 / 220 (1.82%)                                    | 3 / 288 (1.04%)                                    | 4 / 291 (1.37%)         |
| number of deaths (all causes)                                              | 0                                                  | 0                                                  | 0                       |
| number of deaths resulting from adverse events                             |                                                    |                                                    |                         |
| <b>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</b> |                                                    |                                                    |                         |
| <b>Tongue Neoplasm Malignant Stage Unspecified</b>                         |                                                    |                                                    |                         |
| subjects affected / exposed                                                | 0 / 220 (0.00%)                                    | 0 / 288 (0.00%)                                    | 0 / 291 (0.00%)         |
| occurrences causally related to treatment / all                            | 0 / 0                                              | 0 / 0                                              | 0 / 0                   |
| deaths causally related to treatment / all                                 | 0 / 0                                              | 0 / 0                                              | 0 / 0                   |
| <b>Pregnancy, puerperium and perinatal conditions</b>                      |                                                    |                                                    |                         |
| <b>Abortion Spontaneous</b>                                                |                                                    |                                                    |                         |

|                                                      |                 |                 |                 |
|------------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 1 / 291 (0.34%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Gestational Diabetes                                 |                 |                 |                 |
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| General disorders and administration site conditions |                 |                 |                 |
| Drowning                                             |                 |                 |                 |
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Death                                                |                 |                 |                 |
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Reproductive system and breast disorders             |                 |                 |                 |
| Hydrosalpinx                                         |                 |                 |                 |
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Cyst Torsion                                 |                 |                 |                 |
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Ovarian Disorder                                     |                 |                 |                 |
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |
| Vaginal Haemorrhage                                  |                 |                 |                 |
| subjects affected / exposed                          | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all           | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Respiratory, thoracic and mediastinal disorders |                 |                 |                 |
| Pleural Effusion                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 1 / 288 (0.35%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychiatric disorders                           |                 |                 |                 |
| Anxiety Disorder                                |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Anxiety                                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Depression                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Psychotic Disorder                              |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Suicide Attempt                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 1 / 288 (0.35%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 1           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Injury, poisoning and procedural complications  |                 |                 |                 |
| Ankle Fracture                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Gun Shot Wound                                  |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Stab Wound                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cardiac disorders                               |                 |                 |                 |
| Myopericarditis                                 |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Nervous system disorders                        |                 |                 |                 |
| Carotid Artery Dissection                       |                 |                 |                 |
| subjects affected / exposed                     | 1 / 220 (0.45%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Paraesthesia                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 1 / 288 (0.35%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 2           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Myasthenia Gravis                               |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Syncope                                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 1 / 291 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Blood and lymphatic system disorders            |                 |                 |                 |
| Anaemia                                         |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 1 / 291 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| Gastrointestinal disorders                      |                 |                 |                 |
| Abdominal Pain                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 1 / 291 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 2           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Anal Fistula                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Hepatobiliary disorders                         |                 |                 |                 |
| Cholelithiasis                                  |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 1 / 291 (0.34%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 1           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Renal and urinary disorders                     |                 |                 |                 |
| Nephrolithiasis                                 |                 |                 |                 |
| subjects affected / exposed                     | 1 / 220 (0.45%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Musculoskeletal and connective tissue disorders |                 |                 |                 |
| Intervertebral Disc Protrusion                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 220 (0.45%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Infections and infestations                     |                 |                 |                 |
| Appendicitis                                    |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Cellulitis                                      |                 |                 |                 |
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pelvic Abscess                                  |                 |                 |                 |

|                                                 |                 |                 |                 |
|-------------------------------------------------|-----------------|-----------------|-----------------|
| subjects affected / exposed                     | 0 / 220 (0.00%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis                                  |                 |                 |                 |
| subjects affected / exposed                     | 1 / 220 (0.45%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |
| Pyelonephritis Acute                            |                 |                 |                 |
| subjects affected / exposed                     | 1 / 220 (0.45%) | 0 / 288 (0.00%) | 0 / 291 (0.00%) |
| occurrences causally related to treatment / all | 0 / 2           | 0 / 0           | 0 / 0           |
| deaths causally related to treatment / all      | 0 / 0           | 0 / 0           | 0 / 0           |

Frequency threshold for reporting non-serious adverse events: 2 %

| <b>Non-serious adverse events</b>                     | Group 1:<br>Ad26.COV2.S | Group 2:<br>Ad26.COV2.S | Group 6:<br>Ad26.COV2.S<br>1.25x10 <sup>10</sup> vp |
|-------------------------------------------------------|-------------------------|-------------------------|-----------------------------------------------------|
| Total subjects affected by non-serious adverse events |                         |                         |                                                     |
| subjects affected / exposed                           | 245 / 288 (85.07%)      | 187 / 221 (84.62%)      | 217 / 285 (76.14%)                                  |
| Vascular disorders                                    |                         |                         |                                                     |
| Hypertension                                          |                         |                         |                                                     |
| subjects affected / exposed                           | 6 / 288 (2.08%)         | 0 / 221 (0.00%)         | 0 / 285 (0.00%)                                     |
| occurrences (all)                                     | 9                       | 0                       | 0                                                   |
| Nervous system disorders                              |                         |                         |                                                     |
| Headache                                              |                         |                         |                                                     |
| subjects affected / exposed                           | 26 / 288 (9.03%)        | 14 / 221 (6.33%)        | 22 / 285 (7.72%)                                    |
| occurrences (all)                                     | 28                      | 20                      | 28                                                  |
| Headache(Solicited)                                   |                         |                         |                                                     |
| subjects affected / exposed                           | 184 / 288 (63.89%)      | 139 / 221 (62.90%)      | 123 / 285 (43.16%)                                  |
| occurrences (all)                                     | 260                     | 202                     | 165                                                 |
| Blood and lymphatic system disorders                  |                         |                         |                                                     |
| Anaemia                                               |                         |                         |                                                     |
| subjects affected / exposed                           | 5 / 288 (1.74%)         | 1 / 221 (0.45%)         | 0 / 285 (0.00%)                                     |
| occurrences (all)                                     | 5                       | 1                       | 0                                                   |
| Thrombocytopenia                                      |                         |                         |                                                     |
| subjects affected / exposed                           | 8 / 288 (2.78%)         | 5 / 221 (2.26%)         | 9 / 285 (3.16%)                                     |
| occurrences (all)                                     | 8                       | 6                       | 15                                                  |

|                                                      |                    |                    |                    |
|------------------------------------------------------|--------------------|--------------------|--------------------|
| General disorders and administration site conditions |                    |                    |                    |
| Chills                                               |                    |                    |                    |
| subjects affected / exposed                          | 11 / 288 (3.82%)   | 5 / 221 (2.26%)    | 0 / 285 (0.00%)    |
| occurrences (all)                                    | 13                 | 5                  | 0                  |
| Fatigue                                              |                    |                    |                    |
| subjects affected / exposed                          | 15 / 288 (5.21%)   | 11 / 221 (4.98%)   | 15 / 285 (5.26%)   |
| occurrences (all)                                    | 19                 | 14                 | 22                 |
| Fatigue(Solicited)                                   |                    |                    |                    |
| subjects affected / exposed                          | 171 / 288 (59.38%) | 140 / 221 (63.35%) | 132 / 285 (46.32%) |
| occurrences (all)                                    | 248                | 202                | 178                |
| Pyrexia                                              |                    |                    |                    |
| subjects affected / exposed                          | 9 / 288 (3.13%)    | 10 / 221 (4.52%)   | 7 / 285 (2.46%)    |
| occurrences (all)                                    | 14                 | 14                 | 7                  |
| Vaccination Site Erythema(Solicited)                 |                    |                    |                    |
| subjects affected / exposed                          | 3 / 288 (1.04%)    | 5 / 221 (2.26%)    | 5 / 285 (1.75%)    |
| occurrences (all)                                    | 3                  | 5                  | 5                  |
| Pyrexia(Solicited)                                   |                    |                    |                    |
| subjects affected / exposed                          | 68 / 288 (23.61%)  | 41 / 221 (18.55%)  | 16 / 285 (5.61%)   |
| occurrences (all)                                    | 77                 | 42                 | 17                 |
| Vaccination Site Pain                                |                    |                    |                    |
| subjects affected / exposed                          | 7 / 288 (2.43%)    | 8 / 221 (3.62%)    | 8 / 285 (2.81%)    |
| occurrences (all)                                    | 8                  | 12                 | 10                 |
| Vaccination Site Swelling(Solicited)                 |                    |                    |                    |
| subjects affected / exposed                          | 8 / 288 (2.78%)    | 9 / 221 (4.07%)    | 8 / 285 (2.81%)    |
| occurrences (all)                                    | 8                  | 9                  | 9                  |
| Vaccination Site Pain(Solicited)                     |                    |                    |                    |
| subjects affected / exposed                          | 198 / 288 (68.75%) | 156 / 221 (70.59%) | 160 / 285 (56.14%) |
| occurrences (all)                                    | 306                | 242                | 234                |
| Gastrointestinal disorders                           |                    |                    |                    |
| Diarrhoea                                            |                    |                    |                    |
| subjects affected / exposed                          | 6 / 288 (2.08%)    | 3 / 221 (1.36%)    | 2 / 285 (0.70%)    |
| occurrences (all)                                    | 6                  | 3                  | 3                  |
| Nausea                                               |                    |                    |                    |
| subjects affected / exposed                          | 6 / 288 (2.08%)    | 5 / 221 (2.26%)    | 5 / 285 (1.75%)    |
| occurrences (all)                                    | 7                  | 6                  | 6                  |
| Nausea(Solicited)                                    |                    |                    |                    |

|                                                                                                                |                           |                           |                           |
|----------------------------------------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|
| subjects affected / exposed<br>occurrences (all)                                                               | 95 / 288 (32.99%)<br>123  | 78 / 221 (35.29%)<br>99   | 65 / 285 (22.81%)<br>80   |
| Odynophagia<br>subjects affected / exposed<br>occurrences (all)                                                | 3 / 288 (1.04%)<br>3      | 5 / 221 (2.26%)<br>7      | 5 / 285 (1.75%)<br>7      |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)                                                   | 4 / 288 (1.39%)<br>4      | 1 / 221 (0.45%)<br>1      | 2 / 285 (0.70%)<br>3      |
| Respiratory, thoracic and mediastinal disorders<br>Cough<br>subjects affected / exposed<br>occurrences (all)   | 7 / 288 (2.43%)<br>9      | 5 / 221 (2.26%)<br>7      | 4 / 285 (1.40%)<br>5      |
| Dyspnoea<br>subjects affected / exposed<br>occurrences (all)                                                   | 6 / 288 (2.08%)<br>6      | 0 / 221 (0.00%)<br>0      | 1 / 285 (0.35%)<br>1      |
| Musculoskeletal and connective tissue disorders<br>Myalgia<br>subjects affected / exposed<br>occurrences (all) | 10 / 288 (3.47%)<br>12    | 12 / 221 (5.43%)<br>17    | 18 / 285 (6.32%)<br>20    |
| Myalgia(Solicited)<br>subjects affected / exposed<br>occurrences (all)                                         | 183 / 288 (63.54%)<br>260 | 126 / 221 (57.01%)<br>175 | 111 / 285 (38.95%)<br>151 |
| Infections and infestations<br>Influenza<br>subjects affected / exposed<br>occurrences (all)                   | 35 / 288 (12.15%)<br>57   | 26 / 221 (11.76%)<br>31   | 25 / 285 (8.77%)<br>35    |
| Covid-19<br>subjects affected / exposed<br>occurrences (all)                                                   | 9 / 288 (3.13%)<br>14     | 21 / 221 (9.50%)<br>30    | 13 / 285 (4.56%)<br>19    |
| Nasopharyngitis<br>subjects affected / exposed<br>occurrences (all)                                            | 3 / 288 (1.04%)<br>3      | 7 / 221 (3.17%)<br>7      | 12 / 285 (4.21%)<br>13    |
| Rhinitis<br>subjects affected / exposed<br>occurrences (all)                                                   | 8 / 288 (2.78%)<br>9      | 6 / 221 (2.71%)<br>8      | 2 / 285 (0.70%)<br>2      |

| <b>Non-serious adverse events</b>                     | Group 4:<br>Ad26.COV2.S<br>3.5x10 <sup>10</sup> vp | Group 5:<br>Ad26.COV2.S<br>2.5x10 <sup>10</sup> vp | Group 3:<br>Ad26.COV2.S |
|-------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|-------------------------|
| Total subjects affected by non-serious adverse events |                                                    |                                                    |                         |
| subjects affected / exposed                           | 188 / 220 (85.45%)                                 | 228 / 288 (79.17%)                                 | 236 / 291 (81.10%)      |
| Vascular disorders                                    |                                                    |                                                    |                         |
| Hypertension                                          |                                                    |                                                    |                         |
| subjects affected / exposed                           | 4 / 220 (1.82%)                                    | 0 / 288 (0.00%)                                    | 3 / 291 (1.03%)         |
| occurrences (all)                                     | 4                                                  | 0                                                  | 3                       |
| Nervous system disorders                              |                                                    |                                                    |                         |
| Headache                                              |                                                    |                                                    |                         |
| subjects affected / exposed                           | 21 / 220 (9.55%)                                   | 23 / 288 (7.99%)                                   | 11 / 291 (3.78%)        |
| occurrences (all)                                     | 25                                                 | 26                                                 | 12                      |
| Headache(Solicited)                                   |                                                    |                                                    |                         |
| subjects affected / exposed                           | 109 / 220 (49.55%)                                 | 133 / 288 (46.18%)                                 | 146 / 291 (50.17%)      |
| occurrences (all)                                     | 150                                                | 175                                                | 195                     |
| Blood and lymphatic system disorders                  |                                                    |                                                    |                         |
| Anaemia                                               |                                                    |                                                    |                         |
| subjects affected / exposed                           | 0 / 220 (0.00%)                                    | 6 / 288 (2.08%)                                    | 8 / 291 (2.75%)         |
| occurrences (all)                                     | 0                                                  | 7                                                  | 9                       |
| Thrombocytopenia                                      |                                                    |                                                    |                         |
| subjects affected / exposed                           | 7 / 220 (3.18%)                                    | 4 / 288 (1.39%)                                    | 1 / 291 (0.34%)         |
| occurrences (all)                                     | 8                                                  | 5                                                  | 1                       |
| General disorders and administration site conditions  |                                                    |                                                    |                         |
| Chills                                                |                                                    |                                                    |                         |
| subjects affected / exposed                           | 5 / 220 (2.27%)                                    | 4 / 288 (1.39%)                                    | 2 / 291 (0.69%)         |
| occurrences (all)                                     | 6                                                  | 4                                                  | 2                       |
| Fatigue                                               |                                                    |                                                    |                         |
| subjects affected / exposed                           | 9 / 220 (4.09%)                                    | 5 / 288 (1.74%)                                    | 7 / 291 (2.41%)         |
| occurrences (all)                                     | 9                                                  | 5                                                  | 9                       |
| Fatigue(Solicited)                                    |                                                    |                                                    |                         |
| subjects affected / exposed                           | 113 / 220 (51.36%)                                 | 124 / 288 (43.06%)                                 | 144 / 291 (49.48%)      |
| occurrences (all)                                     | 164                                                | 173                                                | 207                     |
| Pyrexia                                               |                                                    |                                                    |                         |
| subjects affected / exposed                           | 4 / 220 (1.82%)                                    | 4 / 288 (1.39%)                                    | 5 / 291 (1.72%)         |
| occurrences (all)                                     | 4                                                  | 4                                                  | 7                       |
| Vaccination Site Erythema(Solicited)                  |                                                    |                                                    |                         |

|                                                                                          |                           |                           |                           |
|------------------------------------------------------------------------------------------|---------------------------|---------------------------|---------------------------|
| subjects affected / exposed<br>occurrences (all)                                         | 4 / 220 (1.82%)<br>4      | 2 / 288 (0.69%)<br>2      | 9 / 291 (3.09%)<br>9      |
| Pyrexia(Solicited)<br>subjects affected / exposed<br>occurrences (all)                   | 27 / 220 (12.27%)<br>27   | 22 / 288 (7.64%)<br>25    | 33 / 291 (11.34%)<br>37   |
| Vaccination Site Pain<br>subjects affected / exposed<br>occurrences (all)                | 3 / 220 (1.36%)<br>4      | 6 / 288 (2.08%)<br>6      | 4 / 291 (1.37%)<br>6      |
| Vaccination Site Swelling(Solicited)<br>subjects affected / exposed<br>occurrences (all) | 3 / 220 (1.36%)<br>3      | 3 / 288 (1.04%)<br>3      | 9 / 291 (3.09%)<br>12     |
| Vaccination Site Pain(Solicited)<br>subjects affected / exposed<br>occurrences (all)     | 153 / 220 (69.55%)<br>231 | 175 / 288 (60.76%)<br>265 | 190 / 291 (65.29%)<br>284 |
| Gastrointestinal disorders                                                               |                           |                           |                           |
| Diarrhoea<br>subjects affected / exposed<br>occurrences (all)                            | 3 / 220 (1.36%)<br>5      | 2 / 288 (0.69%)<br>2      | 3 / 291 (1.03%)<br>4      |
| Nausea<br>subjects affected / exposed<br>occurrences (all)                               | 5 / 220 (2.27%)<br>5      | 5 / 288 (1.74%)<br>5      | 2 / 291 (0.69%)<br>2      |
| Nausea(Solicited)<br>subjects affected / exposed<br>occurrences (all)                    | 58 / 220 (26.36%)<br>71   | 64 / 288 (22.22%)<br>78   | 67 / 291 (23.02%)<br>79   |
| Odynophagia<br>subjects affected / exposed<br>occurrences (all)                          | 1 / 220 (0.45%)<br>1      | 2 / 288 (0.69%)<br>3      | 3 / 291 (1.03%)<br>3      |
| Vomiting<br>subjects affected / exposed<br>occurrences (all)                             | 1 / 220 (0.45%)<br>1      | 1 / 288 (0.35%)<br>1      | 6 / 291 (2.06%)<br>6      |
| Respiratory, thoracic and mediastinal disorders                                          |                           |                           |                           |
| Cough<br>subjects affected / exposed<br>occurrences (all)                                | 7 / 220 (3.18%)<br>7      | 7 / 288 (2.43%)<br>8      | 3 / 291 (1.03%)<br>4      |
| Dyspnoea                                                                                 |                           |                           |                           |

|                                                  |                      |                      |                      |
|--------------------------------------------------|----------------------|----------------------|----------------------|
| subjects affected / exposed<br>occurrences (all) | 1 / 220 (0.45%)<br>2 | 2 / 288 (0.69%)<br>2 | 2 / 291 (0.69%)<br>3 |
| Musculoskeletal and connective tissue disorders  |                      |                      |                      |
| Myalgia                                          |                      |                      |                      |
| subjects affected / exposed                      | 12 / 220 (5.45%)     | 7 / 288 (2.43%)      | 6 / 291 (2.06%)      |
| occurrences (all)                                | 15                   | 7                    | 8                    |
| Myalgia(Solicited)                               |                      |                      |                      |
| subjects affected / exposed                      | 115 / 220 (52.27%)   | 118 / 288 (40.97%)   | 144 / 291 (49.48%)   |
| occurrences (all)                                | 159                  | 159                  | 188                  |
| Infections and infestations                      |                      |                      |                      |
| Influenza                                        |                      |                      |                      |
| subjects affected / exposed                      | 26 / 220 (11.82%)    | 37 / 288 (12.85%)    | 38 / 291 (13.06%)    |
| occurrences (all)                                | 41                   | 52                   | 50                   |
| Covid-19                                         |                      |                      |                      |
| subjects affected / exposed                      | 20 / 220 (9.09%)     | 22 / 288 (7.64%)     | 20 / 291 (6.87%)     |
| occurrences (all)                                | 29                   | 35                   | 28                   |
| Nasopharyngitis                                  |                      |                      |                      |
| subjects affected / exposed                      | 6 / 220 (2.73%)      | 8 / 288 (2.78%)      | 7 / 291 (2.41%)      |
| occurrences (all)                                | 8                    | 13                   | 8                    |
| Rhinitis                                         |                      |                      |                      |
| subjects affected / exposed                      | 4 / 220 (1.82%)      | 10 / 288 (3.47%)     | 1 / 291 (0.34%)      |
| occurrences (all)                                | 4                    | 11                   | 2                    |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date              | Amendment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 08 March 2021     | The purpose of this amendment was to remove the placebo arms of the study for ethical reasons. Furthermore, after consideration of additional COV2001 study results, dose groups of $9 \times 10^{10}$ vp, $7 \times 10^{10}$ vp, and $3.5 \times 10^{10}$ vp Ad26.COV2.S were added and the 1-dose regimen was removed, resulting in 6 dose-groups, each receiving 2 doses.                                                                                                                                                                                                                                                     |
| 10 May 2021       | The purpose of this amendment was to include additional safety measures due to reports of adverse events following use of the Ad26.COV2.S vaccine under emergency use authorisation in the United States (US), suggesting an increased risk of thrombosis combined with thrombocytopenia. Based on this, thrombosis with thrombocytopenia syndrome (TTS), which was a very rare event, followed in this protocol as adverse event of special interest (AESI) that needed to be reported to the sponsor within 24 hours of awareness. In addition, the protocol had been adjusted to align with the latest vaccine risk language. |
| 23 June 2021      | The main purpose of this amendment was to move the Day 85 sampling timepoint (28 days post-dose 2) to Day 71 (14 days post-dose 2) in order to align across VAC31518COVID studies. This amendment also updated the amount of blood volume needed (from 12 millilitre [mL] to 15 mL) to be collected at baseline and for AESI evaluations due to the increased volume of blood needed to isolate serum/plasma for the coagulation related assays in the study. An additional exclusion criterion for subjects with a history of capillary leak syndrome was added.                                                                |
| 03 August 2021    | The purpose of this amendment was to include the mechanism for the rare thrombosis with TTS events that was reported after vaccination with Johnson & Johnson's Ad26.COV2.S vaccine was not known.                                                                                                                                                                                                                                                                                                                                                                                                                               |
| 30 November 2021  | The purpose of this amendment was to clarify that hematology assessment was assessed pre- and post-vaccination in all of the subjects in both the main and sub study. In addition, exploratory endpoints were updated or added in both the main and sub study to include analysis against emerging variants due to the evolving nature of the corona virus-2019 (COVID-19) virus.                                                                                                                                                                                                                                                |
| 01 June 2022      | The purpose of this amendment was to allow flexibility to stop enrollment in the sub-study of seronegative subjects earlier due to the increasing challenges of recruiting seronegative subjects into the sub study. The amendment also removed the interim analysis after the first vaccination at 28 days post dose 1 of the main study.                                                                                                                                                                                                                                                                                       |
| 16 September 2022 | The purpose of this amendment was to modify the order of the sequential non-inferiority assessment hypothesis testing.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported